Neoadjuvant therapy for melanoma: is it ready for prime time?

Beth Helmink; Jennifer A. Wargo

doi:10.1016/S1470-2045(19)30377-8

Neoadjuvant therapy for melanoma: is it ready for prime time?

Beth Helmink
, Jennifer A. Wargo

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	892-894
Number of pages	3
Journal	The Lancet Oncology
Volume	20
Issue number	7
DOIs	https://doi.org/10.1016/S1470-2045(19)30377-8
State	Published - Jul 2019

Access to Document

10.1016/S1470-2045(19)30377-8

Cite this

@article{d5fc5e8865c74d238e02865064d03cb6,

title = "Neoadjuvant therapy for melanoma: is it ready for prime time?",

author = "Beth Helmink and Wargo, \{Jennifer A.\}",

note = "Funding Information: JAW reports compensation for speaker's bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune, and Bristol-Myers Squibb, serves as a consultant or advisory board member for Roche–Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals, and Microbiome DX, and also receives research support from GlaxoSmithKline, Roche–Genentech, Bristol-Myers Squibb, and Novartis. BH is supported by the National Institutes of Health T32 CA 009599 and the MD Anderson Cancer Center support grant ( P30 CA016672 ). The authors would like to acknowledge all of those who have helped make these efforts possible, including the executive committee and the entire membership of the International Neoadjuvant Melanoma Consortium, academic and industry partners, funding agencies and regulatory bodies, as well as the patients who participated in these trials. ",

year = "2019",

month = jul,

doi = "10.1016/S1470-2045(19)30377-8",

language = "English",

volume = "20",

pages = "892--894",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "7",

}

TY - JOUR

T1 - Neoadjuvant therapy for melanoma

T2 - is it ready for prime time?

AU - Helmink, Beth

AU - Wargo, Jennifer A.

N1 - Funding Information: JAW reports compensation for speaker's bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune, and Bristol-Myers Squibb, serves as a consultant or advisory board member for Roche–Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals, and Microbiome DX, and also receives research support from GlaxoSmithKline, Roche–Genentech, Bristol-Myers Squibb, and Novartis. BH is supported by the National Institutes of Health T32 CA 009599 and the MD Anderson Cancer Center support grant ( P30 CA016672 ). The authors would like to acknowledge all of those who have helped make these efforts possible, including the executive committee and the entire membership of the International Neoadjuvant Melanoma Consortium, academic and industry partners, funding agencies and regulatory bodies, as well as the patients who participated in these trials.

PY - 2019/7

Y1 - 2019/7

UR - https://www.scopus.com/pages/publications/85068050201

U2 - 10.1016/S1470-2045(19)30377-8

DO - 10.1016/S1470-2045(19)30377-8

M3 - Comment/debate

C2 - 31171445

AN - SCOPUS:85068050201

SN - 1470-2045

VL - 20

SP - 892

EP - 894

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 7

ER -

Neoadjuvant therapy for melanoma: is it ready for prime time?

Access to Document

Other files and links

Cite this